未登录

P

Pierre K. Alexandre

State University System of Florida

H指数:24

被引数:2,158

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Perspectives on capturing social determinants of health codes in EHRs for new federal policy

关于在新联邦政策下捕捉电子健康记录中健康社会决定因素代码的视角

HEALTH SERVICES RESEARCH

IF3.2

2025-04-060

PRE

The Impact of Market Factors on Meaningful Use of Electronic Health Records Among Primary Care Providers Evidence From Florida Using Resource Dependence Theory and Information Uncertainty Perspective

IF2.8

2024-02-270

PRE

Provider participation in the Florida Medicaid Promoting Interoperability program: Practice characteristics, meaning use attestations, and incentive payments

INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS

IF4.1

2021-06-015

PREAI

Costs of substance use disorders from claims data for Medicare recipients from a population-based sample

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2017-06-013

OAAI

Correlates of nonmedical use of stimulants and methamphetamine use in a national sample

ADDICTIVE BEHAVIORS

IF3.6

2014-05-0141

OAAI

COST EFFECTIVENESS OF COLISTIMETHATE SODIUM FOR THERAPY OF INFECTIONS CAUSED BY MULTIDRUG-RESISTANT (MDR) IN MEXICO

VALUE IN HEALTH

IF6

2014-05-010

OAAI

Interim versus standard methadone treatment: A benefit-cost analysis

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2014-03-0118

OAAI

CLINICAL AND ECONOMIC ANALYSIS OF MOMETASONE FUROATE NASAL SPRAY IN THE TREATMENT OF RHINOSINUSITIS IN MEXICO

VALUE IN HEALTH

IF6

2013-11-010

OAAI

COST ANALYSIS OF PULMONARY ARTERIAL HYPERTENSION IN A TERTIARY CARE SETTING IN MEXICO CITY

VALUE IN HEALTH

IF6

2013-11-010

OAAI

COST-EFFECTIVENESS OF MOMETASONE FUROATE NASAL SPRAY IN THE TREATMENT OF RHINOSINUSITIS IN MEXICO

VALUE IN HEALTH

IF6

2013-05-010

OAAI

Lifetime depressive disorders and adherence to anti-retroviral therapy in HIV-infected Ugandan adults: A case-control study

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2013-02-0132

PREAI

The Economic Cost of Substance Abuse Treatment in the State of Florida

EVALUATION REVIEW

IF3.7

2012-06-177

PREAI

COST-UTILITY ASSESSMENT OF SIROLIMUS VERSUS TACROLIMUS FOR PRIMARY PREVENTION OF GRAFT REJECTION IN RENAL TRANSPLANT RECIPIENTS IN MEXICO

VALUE IN HEALTH

IF6

2012-06-011

OAAI

BUDGET IMPACT ANALYSIS OF FLUTICASONE FUROATE (FFNS) IN TREATMENT OF ALLERGIC RHINITIS PATIENTS IN MEXICO

VALUE IN HEALTH

IF6

2011-11-010

OAAI

COST-EFFECTIVENESS OF FLUTICASONE FUROATE COMPARED WITH MOMETASONA FUROATE FOR THE PRIMARY TREATMENT OF ALLERGIC RHINITIS PATIENTS

VALUE IN HEALTH

IF6

2011-11-010

OAAI

Cost-Effectiveness of Treatment of Salmeterol/Fluticasone in Leukotriene Comparison with Montelukast for Childhood Asthma Control

VALUE IN HEALTH

IF6

2011-07-016

OAAI

Cost Effectiveness of Posaconazole vs. Fluconazole/Itraconazole in Prophylactic Treatment of Invasive Fungal Infections in Mexico

VALUE IN HEALTH

IF6

2011-07-015

OAAI

BUDGET IMPACT MODEL OF ABACAVIR/LAMIVUDINE FOR TREATMENT OF HIV INFECTED PATIENTS IN MEXICO

VALUE IN HEALTH

IF6

2011-05-010

OAAI

Perceived risk associated with ecstasy use: A latent class analysis approach

ADDICTIVE BEHAVIORS

IF3.6

2011-05-0117

OAAI

ECONOMIC EVALUATION OF FLUTICASONE FUROATE COMPARED WITH MOMETASONA FUROATE FOR THE PRIMARY TREATMENT OF ALLERGIC RHINITIS PATIENTS

VALUE IN HEALTH

IF6

2011-05-010

OAAI